- AbbVie has raised its Fiscal Year Adjusted Earnings Per Share (EPS) forecast to between $11.13 and $11.33.
- For the first quarter, the Adjusted EPS was $2.31 which surpassed the estimated $2.23.
- The company attained a net revenue of $12.31 billion, higher than the estimated $11.94 billion.
- Humira revenue was reported at $2.27 billion, a figure above the estimated $2.24 billion.
- Skyrizi’s revenue reached $2.01 billion, surpassing the estimated $1.92 billion.
- Rinvoq’s revenue was reported at $1.09 billion, above the estimated $1.03 billion.
- Imbruvica revenue amounted to $838 million, significantly higher than the estimate of $722.6 million.
- Venclexta revenue has been stated at $614 million, outshining the estimated $579 million.
- Botox – Cosmetic revenue was reported at $633 million, slightly lower than the estimated $693.1 million.
- Botox – Therapeutic revenue reached $748 million, a little less than the estimated $766.4 million.
- Vraylar’s revenue was reported at $694 million which was less than the estimated $711.6 million.
- Ubrelvy’s revenue reached $203 million, higher than the estimated $177.8 million.
- Creon’s revenue was reported at $285 million, lower than the estimated $309.8 million.
- The results reported include an unfavorable impact of $0.08 per share relating to acquired IPR&D and milestones expenses.
- AbbVie’s raised adjusted EPS guidance for 2024 to $11.13 – $11.33 includes an unfavorable impact of $0.08 per share related to acquired IPR&D and milestones expenses.
Abbvie Inc on Smartkarma
Analysts on Smartkarma have been closely covering AbbVie Inc., with recent reports from Baptista Research shedding light on the company’s performance and future prospects.
Baptista Research‘s report titled “AbbVie Inc: Produodopa’s Green Light In Scotland & 6 Other Major Developments – Key Drivers” highlights AbbVie Inc.’s strong performance in the fourth quarter of 2023, surpassing initial expectations. The report emphasizes the company’s growth platform, apart from Humira, showing sales growth exceeding 8% for the full year.
Another report by Baptista Research, “AbbVie Inc.: Is The Strengthening Neuroscience Pipeline The Key To Future Success? – Major Drivers“, discusses AbbVie Inc.’s ability to exceed Wall Street’s revenue and earnings expectations, indicating positive long-term growth prospects. The report underscores the strength of the ex-HUMIRA growth platform, achieving remarkable revenue growth of over 12% in the quarter.
A look at Abbvie Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Abbvie Inc, a leading pharmaceutical company, has garnered a positive long-term outlook based on the Smartkarma Smart Scores. With a strong Dividend score of 4 and Momentum score of 4, the company is positioned well for future growth and stability. Abbvie’s focus on research and development in specialty therapeutic areas like immunology, oncology, and neuroscience bodes well for its continued success.
The company’s Growth score of 3 indicates potential for expansion, while its Value and Resilience scores of 2 each suggest room for improvement in these areas. Abbvie’s diverse portfolio of pharmaceutical products, including treatments for chronic diseases like Multiple Sclerosis and Alzheimer’s, provides a solid foundation for sustained performance in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
